Solventum Income Statement
SOLV / Health Care|4 years of annual SEC 10-K data (FY2022-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
Solventum reported $8.3B in revenue and $1.6B in net income for FY2025. Revenue has grown at a 0.8% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 30.6%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $8.3B | $8.3B | $8.2B | $8.1B |
| Gross Profit | $4.5B | $4.6B | $4.7B | $4.7B |
| SG&A Expense | $3.1B | $2.8B | $2.3B | $2.2B |
| R&D Expense | $739.0M | $775.0M | $758.0M | $767.0M |
| Operating Income | $2.2B | $1.0B | $1.7B | $1.7B |
| Income Tax | $157.0M | $127.0M | $321.0M | $349.0M |
| Net Income | $1.6B | $479.0M | $1.3B | $1.3B |
| EPS (Basic) | $7.79 | $7.78 | $7.79 | $7.78 |
| EPS (Diluted) | $7.79 | $7.78 | $7.79 | $7.78 |
| Shares Outstanding | 0 | 0 | 172.7M | 172.7M |
| Gross Margin | 53.5% | 55.6% | 57.3% | 57.7% |
| Operating Margin | 26.2% | 12.6% | 20.6% | 20.8% |
| Profit Margin | 18.7% | 5.8% | 16.4% | 16.5% |